Eyenovia updates corporate presentation; MicroPine interim readout 4Q 2024, Clobetasol launch 3Q 2024

HYPERION DEFI, INC.

MicroPine Phase 3 CHAPERONE interim DMC review expected 4Q 2024; SAE rate <1 per 1,000 patient-months, all unrelated.
Clobetasol propionate 0.05% launch expected 3Q 2024; projected 3rd-year sales $50M; co-promotion with NovaBay for Avenova.
Optejet Gen-2 FDA meeting planned 3Q 2024 to confirm pathway for drug/device; licensing targets dry eye and glaucoma (>$8.8B market).
MicroPine potential peak US sales >$1B by 2036; net price $200/month, COGS <$20; addresses ~5M high-risk myopic children.
Optecare digital compliance system built into Optejet to track adherence; aims to improve patient outcomes and differentiate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.